(UroToday.com) The neutrophil-to-lymphocyte ratio (NLR) could be established as an important prognostic marker for the outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with chemotherapy, steroids, and novel androgen receptor directed therapies. Thus far, the value of the NLR as a biomarker in the context of therapeutic radionuclides has never been explored. At the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. Alexander Meisel and colleagues presented results assessing the impact of the NLR as a biomarker as a post-hoc analysis of the phase III ALSYMPCA trial.